Having trouble accessing articles? Reset your cache.

Anacor still climbing on Phase II dermatitis data

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) gained an additional $1.24 (26%) to $6.08 on Friday after reporting data on Thursday

Read the full 184 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE